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Abstract
Introduction The receptor for advanced glycation end products
(RAGE), a multi-ligand member of the immunoglobulin
superfamily, contributes to acute and chronic disease
processes, including sepsis.
Methods We studied the possible therapeutic role of RAGE
inhibition in the cecal ligation and puncture (CLP) model of
polymicrobial sepsis and a model of systemic listeriosis using
mice genetically deficient in RAGE expression or mice injected
with a rat anti-murine RAGE monoclonal antibody.
Results The 7-day survival rates after CLP were 80% for RAGE-
/- mice (n = 15) (P < 0.01 versus wild-type), 69% for RAGE+/-
mice (n = 23), and 37% for wild-type mice (n = 27). Survival
benefits were evident in BALB/c mice given anti-RAGE antibody
(n = 15 per group) over serum-treated control animals (P <
0.05). Moreover, delayed treatment with anti-RAGE antibody up
to 24 hours after CLP resulted in a significant survival benefit
compared with control mice. There was no significant increase
in tissue colony counts from enteric Gram-negative or Gram-
positive bacteria in animals treated with anti-RAGE antibody.
RAGE-/-, RAGE+/-, and anti-RAGE antibody-treated animals
were resistant to lethality from Listeria monocytogenes by
almost two orders of magnitude compared with wild-type mice.
Conclusion Further studies are warranted to determine the
clinical utility of anti-RAGE antibody as a novel treatment for
sepsis.
Introduction
Sepsis is a major clinical problem in acute care medicine and
surgery, and treatment options remain limited [1,2]. This unmet
medical need has inspired a great deal of work to understand
the molecular pathogenesis of sepsis and to develop improved
therapeutic interventions. One molecule that has been impli-
cated in the pathogenesis of sepsis is the receptor for
advanced glycation end products (RAGE), a member of the
immunoglobulin (Ig) superfamily [3,4]. It consists of an extra-
cellular domain comprised of an Ig-like V-type domain and two
Ig-like C-type domains, a single membrane-spanning domain,
and a cytosolic tail [3]. The V-type domain and the cytoplasmic
domain are important for ligand binding and for intracellular
signaling, respectively. In addition to membrane-bound RAGE,
soluble forms of RAGE (sRAGE) have been detected in
plasma. Although the physiologic function of RAGE is unclear,
it is involved in the inflammatory response and may have a role
in neural development [5].
In several animals models, modulation of RAGE expression or
activity has reduced inflammatory responses. In a model of
delayed-type hypersensitivity, mice sensitized to methylated
bovine serum albumin (mBSA) and administered sRAGE or
anti-RAGE antibody (F(ab)2  fragment) had decreased
AGE = advanced glycation end products; CFU = colony-forming units; CLP = cecal ligation and puncture; HMGB-1 = high-mobility group box-1; Ig 
= immunoglobulin; IL = interleukin; IUCAC = Institutional Animal Care and Use Committee; LD50 = median lethal dose; mAb = monoclonal antibody; 
mBSA = methylated bovine serum albumin; MCP-1 = monocyte chemoattractant protein-1; ns = not significant; RAGE = receptor for advanced gly-
cation end products; sRAGE = soluble receptor for advanced glycation end products; TNF = tumor necrosis factor; TSB = trypticase soy broth.Critical Care    Vol 11 No 6    Lutterloh et al.
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inflammation following mBSA challenge [6]. In a study of
chronic inflammation using an interleukin (IL)-10 null model of
colitis, 6 weeks of treatment with sRAGE decreased the
number of mice with colitis [6]. In streptozotocin-treated dia-
betic mice, sRAGE reduced periodontitis in mice challenged
with  Porphyromonas gingivalis [7]. Additionally, sRAGE
reduced neutrophil extravasation into the peritoneum in thi-
oglycollate-induced peritonitis in diabetic mice [8]. Reduced
neutrophil migration into the peritoneum was also observed in
RAGE-/- mice [9]. These studies suggest a role for RAGE in
several disease settings.
RAGE is expressed at low levels on multiple cell types. Expres-
sion is increased upon ligand interaction in chronic disease
states such as rheumatoid arthritis [8,10] and diabetic neph-
ropathy [11]. Ligands include advanced glycation end prod-
ucts (AGEs) which form in prolonged hyperglycemic states.
However, AGEs may be only incidental, pathogenic ligands
[6,12]. RAGE is a pattern-recognition receptor that binds
diverse classes of endogenous molecules. Known ligands
include high-mobility group box-1 (HMGB-1) [12], the S100/
calgranulins [6], and peptides with a three-dimensional struc-
ture consisting of beta-sheet fibrils, such as amyloid [5,13].
RAGE is also a counter-receptor for the beta2-integrins Mac-1
and p150, 95 [9]. RAGE is part of a newly appreciated com-
ponent of the innate immune system referred to as the dam-
age-associated molecular pattern system [14,15].
HMGB-1 is an inflammatory cytokine and RAGE ligand that
may be important in the septic response [6,12,16]. HMGB-1,
also a DNA-binding protein, is released from cells due to
necrosis or via a non-classical secretion pathway and is a late-
stage mediator of lethality in a murine model of sepsis. Many
of the RAGE ligands represent a unique class of molecules
with both intra- and extracellular activities [14,15]. In a study
using the cecal ligation and puncture (CLP) model of pol-
ymicrobial sepsis, HMGB-1 levels increased over the span of
1 to 2 days after CLP and remained elevated during the course
of disease [17]. Mortality decreased in this model with admin-
istration of anti-HMGB-1 antibody. An in vitro study showed
that activation of human umbilical venular endothelial cells by
HMGB-1 was partially decreased by anti-RAGE antibodies
given with the HMGB-1 [18]. The anti-RAGE antibodies did
not affect stimulation with lipopolysaccharide or tumor necro-
sis factor (TNF)-α, implying that some elements of the inflam-
matory response induced by HMGB1 are mediated by RAGE.
In a study by Liliensiek and colleagues [19], the genomic dele-
tion of RAGE resulted in a decreased septic response, 80%
of RAGE knockout mice survived the lethal effects of CLP,
whereas only 20% of wild-type mice survived. Administration
of sRAGE to block RAGE ligands also increased survival to
40% compared with 17% in the control group. There were
fewer inflammatory cells on the peritoneum of RAGE-/- mice
compared with wild-type mice after CLP; however, cytokine
levels and inflammatory cells in the blood were similar between
wild-type mice and RAGE-/- mice. The study suggests that
RAGE may be a mediator in polymicrobial sepsis and that
modulation may affect the pathophysiology.
We hypothesized that treatment with an anti-RAGE antibody
may have a protective effect in polymicrobial sepsis. Our
experiments show that the administration of a rat anti-murine
RAGE increased survival in the CLP model of sepsis com-
pared with mice given control serum, even with delayed admin-
istration as long as 24 hours after CLP. Additionally, our
studies confirm the finding that homozygous RAGE knockout
mice survive polymicrobial sepsis at a higher rate compared
with wild-type mice and show that heterozygous RAGE+/- mice
have a similar survival rate. Finally, we show that RAGE-/- and
RAGE+/- mice and RAGE monoclonal antibody (mAb)-treated
mice also survive a systemic Listeria monocytogenes chal-
lenge significantly better than wild-type mice. These results
demonstrate that RAGE may play an important role in the
pathogenesis of sepsis in the CLP model and that anti-RAGE
mAbs can increase the survival of septic mice.
Materials and methods
Materials and bacterial strains
Reagents and chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA) unless otherwise stated. The IgG2b anti-
murine RAGE mAb was developed by Wyeth (Cambridge,
MA, USA). This mAb is a high-affinity rat-derived anti-mouse
RAGE antibody with a binding affinity of 0.3 nM for murine
dimeric RAGE and binds to the N-terminal region of RAGE.
Specificity of the antibody was demonstrated by binding to
RAGE on the cell surface, direct binding to sRAGE, and immu-
nohistochemistry (manuscript in preparation). Endotoxin levels
were measured in all antibody preparations and were less than
1 endotoxin unit/mg protein. The high-affinity IgG hamster anti-
TNF-α neutralizing mAb TN3.1912 was provided as a gift from
Celltech LTD (Slough, Berkshire, UK). The challenge strain of
L. monocytogenes was purchased from American Type Cul-
ture Collection (ATCC # 19115; Manassas, VA, USA).
Animal strains and animal husbandry
Mouse strains used in these experiments were 2 to 6 months
old and were specific-pathogen-free. BALB/c mice (Charles
River Laboratories, Inc., Wilmington, MA, USA), homozygous
RAGE-/-  129SvEvBrd male mice, heterozygous RAGE+/-
129SvEvBrd male mice, and wild-type RAGE+/+ 129SvEvBrd
male mice (bred in-house at Wyeth) were used. The RAGE
knockout mouse was designed at Wyeth Research (gener-
ated at Lexicon Genetics Incorporated, The Woodlands, TX,
USA) as a gene targeted conditional knockout in 129SvEv-
Brd mice in which Cre recombinase excises exons 2, 3, and 4.
The resulting deletion results in a frame shift and truncation of
the RAGE protein, and protein is not produced. The absence
of RAGE protein in the RAGE-/- mice was confirmed by West-
ern immunoblot analysis of lung tissue lysates. Lungs wereAvailable online http://ccforum.com/content/11/6/R122
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harvested from individual RAGE+/+, RAGE+/-, and RAGE-/- ani-
mals and were flash-frozen. The tissue was lysed with radio-
immunoprecipitation assay buffer. Equivalent amounts of total
protein from each sample were analyzed by electrophoresis on
a NuPAGE 4% to 12% Bis-Tris gel (Invitrogen Corporation,
Carlsbad, CA, USA) and detected with immunodetection with
the RAGE mAb or actin antibody and a horseradish peroxi-
dase-conjugated anti-donkey antibody using standard proto-
cols. RAGE is not essential for viability in mice; RAGE null
mice have no obvious phenotype and breed normally.
Animals were housed in an Institutional Animal Care and Use
Committee (IUCAC)-approved facility under Biosafety Level 2
conditions and monitored by Brown University veterinary staff.
Cages were covered with high-efficiency particulate air filters
and maintained at constant ambient temperature and humidity
with 12-hour day-night cycling. Animals were provided with an
ad libitum supply of commercial mouse chow and distilled
water and allowed to adjust to laboratory conditions for at least
7 days before undergoing experimental procedures. The
experimental protocol was approved by the IUCAC before any
procedures were undertaken.
Cecal ligation and puncture model
The CLP procedure has been described previously [20].
Briefly, animals were anesthetized with an intraperitoneal injec-
tion of 200 μL of a combination of ketamine (Bedford Labora-
tories, Bedford, OH, USA) (9 mg/mL) and xylazine (Phoenix
Pharmaceutical, Inc., St. Joseph, MO, USA) (1 mg/mL). The
cecum was exteriorized through a midline abdominal incision
of approximately 1 cm. The cecum was ligated with 5.0 mono-
filament just distal to the ileocecal junction (greater than 90%
of the cecum ligated). The ante-mesenteric side of the cecum
was punctured through and through with a 23-gauge needle.
A scant amount of luminal content was expressed through
both puncture sites to ensure patency. The cecum was
returned to the abdominal cavity, and the fascia and skin inci-
sions were closed with 6.0 monofilament and surgical staples,
respectively. Topical 1% lidocaine and bacitracin were applied
to the surgical site post-operatively. All animals received a sin-
gle intramuscular injection of trovafloxacin (Pfizer Inc, New
York, NY, USA) at a dose of 20 mg/kg and subcutaneous fluid
resuscitation with 1.0 mL of normal saline immediately post-
operatively. Animals were then returned to their individual
cages and rewarmed using heat lamps until they regained nor-
mal posture and mobility.
Anti-RAGE mAb at 7.5 mg/kg or 15 mg/kg (or 1% autologous
mouse serum control) was given once intravenously to wild-
type 129SvEvBrd or BALB/c mice 30 to 60 minutes before
CLP or at the following time intervals after CLP: 6, 12, 24, or
36 hours. Five animals underwent sham surgery (laparotomy
with exteriorization of the cecum but without ligation or punc-
ture). Mice were assessed for survival up to 7 days following
surgery.
Murine listeriosis challenge model
A standard inoculum of L. monocytogenes was prepared from
cultures grown 18 hours at 37°C in trypticase soy broth (TSB)
(BBL, Cockeysville, MD, USA). Bacteria were centrifuged at
10,000g for 15 minutes at 4°C and resuspended in phos-
phate-buffered saline. Bacterial concentrations were adjusted
spectrophotometrically and checked by quantitative dilutional
plate counts on trypticase soy agar plates with 5% sheep red
blood cells (BBL). Serial dilutions ranging from 103 to 106 col-
ony-forming units (CFU) of L. monocytogenes were adminis-
tered intravenously to determine the median lethal dose (LD50)
for wild-type mice, homozygous RAGE-/- knockouts, RAGE+/-
heterozygotes, and BALB/c mice given 15 mg/kg anti-RAGE
mAb intravenously 1 hour before bacterial challenge. Animals
were followed for 7 days after the administration of the intrave-
nous challenge with L. monocytogenes. Survivors were euth-
anized for tissue analysis and microbiologic study.
For the detailed differential quantitative microbiology and
cytokine determinations, a standard inoculum of 104 CFU was
given intraperitoneally 1 hour after an intravenous infusion of
anti-RAGE mAb (15 mg/kg), anti-TNF mAb (20 mg/kg), or
equal volume of 1% autologous murine serum as a control.
RAGE+/+, RAGE+/-, and RAGE-/- mice were also studied (n =
5 per group). Animals were euthanized 48 hours after L.
monocytogenes challenge, and quantitative microbiology was
performed from liver and spleen tissues by mincing the tissue
samples with serial dilution on blood agar plates.
Injections and manipulations of the animals were conducted
under light CO2 anesthesia to minimize stress to the experi-
mental animals. Animals were monitored daily for survival. Mor-
ibund animals (hypothermia below 33°C and inactive with loss
of righting response) were euthanized and scored as lethally
infected animals.
Tissue collection and cytokine measurement
Quantitative microbiology was performed from organ samples
obtained at necropsy in both the CLP and listeriosis experi-
ments. Blood samples were obtained from surviving animals at
the time of sacrifice, and serum was collected and immediately
placed on ice for cytokine determination. Serum cytokines
were measured by an enzyme-linked immunosorbent multiplex
assay using the custom-made plates and protocol provided by
Meso Scale Discovery (Gaithersburg, MD, USA). Cytokines
assayed were monocyte chemoattractant protein-1 (MCP-1),
IL-1-β, TNF-α, interferon-γ, and IL-6. Tissue samples were col-
lected from the lung, liver, and spleen. Peritoneal fluid was
obtained by lavaging the peritoneal cavity with 5 mL of sterile
saline and withdrawing the fluid. Organ tissues were weighed
and then pulverized to generate a suspension of tissue in TSB.
Specimens were serially diluted and cultured at 37°C aerobi-
cally on TSB (for Gram-negative and Gram-positive bacteria)
and MacConkey agar (for Gram-negative bacteria) to obtainCritical Care    Vol 11 No 6    Lutterloh et al.
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quantitative bacterial counts standardized per gram of organ
weight or CFU per milliliter of peritoneal lavage fluid.
Tissues (lung, distal ileum) were analyzed by a pathologist
blinded to the treatment assignment of each animal and
scored on a defined pathology score graded from 0 (normal)
to 4 (diffuse and extensive necrosis). Total lung water as a
measure of pulmonary edema was calculated from wet-to-dry
ratios of lung tissue.
Statistical design and data analysis
The primary endpoint in each experiment was survival. Experi-
ments were performed using a numeric code that blinded the
investigators to the animal genotype or antibody treatment
(versus serum control) until completion of the study. Numeric
data are presented as mean (± standard error of the mean).
Differences in survival were analyzed by a Kaplan-Meier sur-
vival plot and the log-rank statistic. The non-parametric one-
way analysis of variance statistic Kruskal-Wallis test (for multi-
ple groups) or the Mann-Whitney U test (for two groups) was
used to analyze differences between groups. The Dunn multi-
ple comparisons post-test was used to confirm differences
when analyzing comparisons involving multiple groups. A two-
tailed P value of less than 0.05 was considered significant.
Results
Survival of homozygous RAGE knockouts, RAGE 
heterozygotes, and wild-type animals after cecal ligation 
and puncture
Homozygous RAGE knockouts (n = 15) and RAGE heterozy-
gotes (n = 23) showed a significant degree of protection from
the lethal effects of CLP compared with wild-type RAGE +/+
animals (n = 15) (P < 0.001) (Figure 1). RAGE heterozygotes
were protected from lethal polymicrobial sepsis nearly as well
as the homozygous RAGE knockouts (RAGE-/- versus RAGE+/
-; P = not significant [ns]). As expected, sham surgery animals
(n  = 5) all survived. An additional group of 15 wild-type
129SvEvBrd animals were given anti-RAGE mAb 30 to 60
minutes before CLP and had a survival advantage similar to
that of the RAGE knockouts when compared with the wild-
type, serum-treated, control animals (Figure 1).
The expression of RAGE protein was examined by Western
immunoblot analysis of lung tissue where RAGE is constitu-
tively expressed at high levels. In contrast to the expression of
RAGE in RAGE +/+ mice, no RAGE protein was detected in
the lungs of RAGE-/- mice. The levels of expression in RAGE+/
- mice were reduced compared with wild-type mice (Figure 2).
Tissue colony counts for aerobic Gram-positive and Gram-
negative enteric bacterial organisms following CLP were
assessed to determine whether RAGE knockouts, RAGE het-
erozygotes, or anti-RAGE mAb-treated mice were different
from wild-type mice or control-treated mice. No significant dif-
ferences were found in liver and splenic tissues and peritoneal
fluid, except that all were significantly higher than in sham-
operated animals. The homozygous RAGE knockouts had the
lowest amount of lung water compared with other groups,
although this did not reach significance (wet-to-dry ratio: 4.8
± 0.2 RAGE-/- versus 5.0 ± 0.4 RAGE+/- versus 5.3 ± 0.3 wild-
type; P = ns).
Effects of anti-RAGE antibody with cecal ligation and 
puncture
There was a significant difference in survival in BALB/c ani-
mals given control serum (n = 15) compared with animals
given anti-RAGE antibody (7.5 mg/kg group [n = 15] or 15
mg/kg group [n = 15]) 30 to 60 minutes before CLP (Figure
3). Optimal protective effects were achieved at 15 mg/kg of
anti-RAGE mAb (P < 0.05 versus 7.5 mg/kg group; P < 0.001
versus serum control), and this dose was employed in subse-
quent experiments with delayed mAb treatment. Animals given
anti-RAGE antibody did not have significantly increased organ
bacterial loads compared with control animals, but both
groups had significantly more CFU/g of spleen and liver tissue
than sham-treated control animals (Table 1). Histopathology of
lung tissue and small bowel mucosa at necropsy was markedly
abnormal in the serum control group, whereas pathological
findings were significantly reduced in the anti-RAGE mAb
group and the sham surgery group (Table 1).
Survival of animals with delayed administration of anti-
RAGE mAb after cecal ligation and puncture
The effects of delayed administration of a single 15 mg/kg
dose of anti-RAGE antibody are shown in Figure 4. The admin-
istration of RAGE mAb provided significant protection up to
24 hours after CLP (P < 0.01). Delayed mAb administration
36 hours after CLP showed a favorable survival trend, but the
differences were no longer significant compared with the
serum-treated control group (P = 0.12). The tissue concentra-
tions of aerobic enteric Gram-negative and Gram-positive bac-
teria did not differ between treatment groups (P = ns).
Listeria monocytogenes challenge
When challenged with L. monocytogenes, the LD50 (log10) val-
ues were 3.30 ± 0.12 for BALB/c mice, 3.31 ± 0.2 CFU for
RAGE+/+ 129SvEvBrd mice, 5.98 ± 0.39 for RAGE+/- mice,
and 5.10 ± 0.47 for RAGE-/- mice. This difference of more than
two orders of magnitude in LD50 from systemic listeriosis was
statistically significant (P < 0.01) for both the RAGE heterozy-
gotes and homozygotes compared with wild-type mice. A sin-
gle dose of anti-RAGE antibody also provided BALB/c mice
significant protection from lethal systemic listeriosis with an
LD50 of 4.69 ± 0.55 (P < 0.05 versus BALB/c control). The
level of protection against listeriosis provided by the anti-
RAGE mAb was similar to that observed in RAGE-/- animals
but was not as great as that afforded RAGE+/- animals (P <
0.05).Available online http://ccforum.com/content/11/6/R122
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Figure 1
Modulation of receptor for advanced glycation end products (RAGE) protects mice from the effects of cecal ligation and puncture (CLP) Modulation of receptor for advanced glycation end products (RAGE) protects mice from the effects of cecal ligation and puncture (CLP). Kaplan-
Meier survival analysis following CLP comparing wild-type RAGE+/+ 129SvEvBrd mice (n = 15), RAGE-/- mice (n = 15), RAGE+/- mice (n = 23), and 
anti-RAGE monoclonal antibody-treated (15 mg/kg intravenously 30 to 60 minutes before CLP) wild-type mice (n = 15). P < 0.001 for each group 
in comparison with the wild-type CLP control group. Sham surgery-treated wild-type 129SvEvBrd mice (n = 5) were used as an additional control 
group. WT, wild-type.
Figure 2
Receptor for advanced glycation end products (RAGE) protein expression in lung tissue from individual RAGE-/- (lanes 1 to 3), RAGE+/- (lanes 4 to  6), and RAGE+/+ (lanes 7 to 9) animals Receptor for advanced glycation end products (RAGE) protein expression in lung tissue from individual RAGE-/- (lanes 1 to 3), RAGE+/- (lanes 4 to 
6), and RAGE+/+ (lanes 7 to 9) animals. Actin was used to demonstrate equal loading.
Table 1
Microbiologic and pathologic findings following anti-RAGE mAb therapy in cecal ligation and puncture
Parameter Sham Serum control Anti-RAGE mAb (15 mg/kg)
Number of mice 5 15 15
Aerobic Gram-negative bacteria (CFU/g) 0.6 ± 1.5a 5,643 ± 1,281 4,910 ± 395
Aerobic Gram-positive bacteria (CFU/g) 601 ± 548a 15,616 ± 6,800 11,222 ± 1,873
Pathology score (lung, small bowel) 0.6 ± 0.5 3.0 ± 0.9b 1.8 ± 1.1
Wet-to-dry ratio (lung tissue) 4.6 ± 0.6 5.3 ± 0.5 5.1 ± 0.6
aP < 0.05 sham versus other groups; bP < 0.005 control versus sham or anti-RAGE mAb. CFU, colony-forming units; mAb, monoclonal antibody; 
RAGE, receptor for advanced glycation end products.Critical Care    Vol 11 No 6    Lutterloh et al.
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There was no statistically significant difference in the quantity
of L. monocytogenes isolated in liver and spleen tissues fol-
lowing a standard systemic challenge of 104 CFU among
groups (n = 10 per group) of RAGE+/+ mice, RAGE-/- mice,
RAGE+/- mice, or BALB/c mice given anti-RAGE mAb (Figure
5). However, as expected, there was a highly statistically sig-
nificant increase in organ bacterial concentrations in BALB/c
mice given the same inoculum of L. monocytogenes following
the administration of an anti-TNF antibody (P < 0.001).
Cytokine determinations after Listeria challenge showed a sig-
nificantly lower level of interferon-γ in RAGE-/- mice compared
with RAGE+/+ mice (Figure 6). The BALB/c mice administered
anti-TNF mAb had a significantly higher level of interferon-γ
compared with BALB/c controls, whereas the animals given
anti-RAGE mAb had interferon-γ levels that were not statisti-
cally different compared with control animals. Similar results
were observed with IL-6 (anti-TNF mAb group 459 ± 121 pg/
mL versus control group 38 ± 14 pg/mL; P < 0.01) and MCP-
Figure 3
Lethality from cecal ligation and puncture (CLP) is decreased in BALB/c mice administered an anti-RAGE monoclonal antibody (mAb) Lethality from cecal ligation and puncture (CLP) is decreased in BALB/c mice administered an anti-RAGE monoclonal antibody (mAb). The Kaplan-
Meier survival analysis following CLP compares anti-RAGE mAb-treated animals given 7.5 mg/kg (n = 15) or 15 mg/kg (n = 15) intravenously 30 to 
60 minutes before CLP with serum control animals (n = 15). The group given 15 mg/kg had a significantly greater survival than the group given 7.5 
mg/kg (P < 0.05) or serum control (P < 0.001). RAGE, receptor for advanced glycation end products.
Figure 4
Delayed administration of the anti-RAGE antibody is protective in cecal ligation and puncture (CLP) Delayed administration of the anti-RAGE antibody is protective in cecal ligation and puncture (CLP). The Kaplan-Meier survival analysis following 
CLP in BALB/c mice compares delayed anti-RAGE monoclonal antibody (mAb) treatment given at various time intervals after CLP with serum con-
trol. Each group had a significantly greater survival than the control group (P < 0.01), except for the 36-hour delayed treatment group (P = 0.12). 
RAGE, receptor for advanced glycation end products.Available online http://ccforum.com/content/11/6/R122
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1 (anti-TNF mAb 1,363 ± 480 pg/mL versus control group
566 ± 70 pg/mL; P < 0.05). No significant differences were
found in IL-6 or MCP-1 levels in RAGE-deficient animals or in
anti-RAGE antibody-treated mice compared with the control
group. Other cytokine determinations showed no significant
differences.
Discussion
These results support the beneficial effects of treatment with
anti-RAGE antibody in a standard murine model of
polymicrobial, intra-abdominal sepsis. We have confirmed that
homozygous RAGE knockouts have increased survival com-
pared with wild-type mice in the CLP model of sepsis. In addi-
tion, heterozygous RAGE+/-  mice were similarly protected
compared with wild-type mice. RAGE suppression did not
increase tissue colony counts from enteric Gram-negative or
Gram-positive bacteria. These results show that the modula-
tion of RAGE protected mice from the lethal effects of CLP-
induced sepsis. RAGE expression is highly detrimental to ani-
mals challenged systemically with L. monocytogenes as evi-
denced by the marked survival benefits observed in
homozygous RAGE knockouts and heterozygotes compared
with wild-type animals. The precise mechanism of these bene-
fits is unclear and under investigation.
The finding that homozygous and heterozygous RAGE knock-
out mice survive sepsis at higher rates than wild-type animals
seems counterintuitive from an evolutionary standpoint. Spec-
ulation as to the reason for the persistence of a widely
expressed and seemingly disadvantageous gene in the mam-
malian genome is hampered by the lack of a detailed under-
standing of RAGE's physiologic role. An intriguing finding is
that, contrary to many systems designed to maintain homeos-
tasis, RAGE expression is increased in inflammatory states
when it binds to its ligands [21,22]. This positive feedback
mechanism might function counter to homeostatic mecha-
nisms in the presence of a massive inflammatory insult and
hasten death of a severely ill animal.
Given the finding of increased survival with polymicrobial sep-
sis in RAGE knockout animals, we hypothesized that treatment
with an anti-RAGE antibody would increase survival. Our
RAGE knockout animals, however, may have developed com-
pensatory mechanisms that alter their inflammatory response.
The experiment showing increased survival in animals admin-
istered the anti-RAGE antibody confirms that the benefit is
present in situations in which physiologic compensation for
genetic deficiency could not have occurred. This opens up an
entirely new avenue for the treatment of severe sepsis and
suggests that inhibition of the RAGE pathway may be an effec-
tive approach for treatment of sepsis in clinical settings.
Activation of the RAGE receptor triggers signaling cascades
leading to sustained cellular activation, increase of RAGE
itself, and propagation of the response. HMGB-1 and other
RAGE ligands may contribute to damage and host response
as part of the danger-associated molecular pattern system
[14,15]. In animal models, HMGB-1 is a mediator of severe
sepsis, and an anti-HMGB-1 antibody decreased mortality in
the CLP model of sepsis [6,12,16]. In this study, the
administration of anti-RAGE mAb and a genetic deletion of
RAGE conferred resistance to the lethal effects of CLP. Addi-
tionally, delayed treatment with the anti-RAGE antibody up to
24 hours after CLP resulted in a significant survival benefit,
suggesting that disruption of the interaction between RAGE
and RAGE ligands is beneficial in this setting.
Figure 5
Inhibition or deletion of receptor for advanced glycation end products  (RAGE) does not disrupt the host mechanism for clearance of Listeria  monocytogenes Inhibition or deletion of receptor for advanced glycation end products 
(RAGE) does not disrupt the host mechanism for clearance of Listeria 
monocytogenes. Quantitative levels of L. monocytogenes in organ 
samples (liver and spleen, n = 10 per group) 48 hours after an intra-
peritoneal injection of 104 colony-forming units (CFU) per animal (P < 
0.001 anti-tumor necrosis factor [TNF] monoclonal antibody [mAb] 
group versus all other groups).
Figure 6
Interferon-gamma levels following intraperitoneal challenge with 104  colony-forming units (CFU) of Listeria monocytogenes are shown (n =  10 for each group) Interferon-gamma levels following intraperitoneal challenge with 104 
colony-forming units (CFU) of Listeria monocytogenes are shown (n = 
10 for each group). P < 0.05 for anti-tumor necrosis factor (TNF) mon-
oclonal antibody (mAb) group and RAGE-/- group, both versus control 
group. RAGE, receptor for advanced glycation end products.Critical Care    Vol 11 No 6    Lutterloh et al.
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Systemic L. monocytogenes challenge is a classic model for
study of the innate and acquired immune response in mice
[23,24]. RAGE blockade or insufficiency due to administration
of anti-RAGE antibody or as observed in RAGE null or RAGE
heterozygous animals did not produce significant sensitivity to
the Listeria challenge compared with wild-type animals, indi-
cating that the deleterious effects of RAGE are present in an
inflammatory state other than that accompanying polymicro-
bial sepsis. Mice administered anti-RAGE mAb and RAGE
knockout animals appear to clear L. monocytogenes as well as
wild-type animals. This is in contrast to animals given anti-TNF
antibody in which the L. monocytogenes colony counts in tis-
sue samples were markedly increased. Previous studies have
demonstrated that anti-TNF antibodies suppress the innate
immune response and increase the sensitivity to challenge.
Similarly, cytokine levels were increased after Listeria chal-
lenge in animals given anti-TNF mAb. However, the levels were
similar in animals given the anti-RAGE antibody and the con-
trol animals, consistent with no increase in sensitivity to the
Listeria challenge.
The finding of a survival benefit after delayed administration of
anti-RAGE antibody was encouraging. This may have impor-
tant clinical implications since an intervention such as anti-
RAGE antibody treatment typically cannot be given immedi-
ately after the inciting event in septic patients.
Conclusion
These data provide support for the use of anti-RAGE mAb as
a salvage therapy for patients with established severe sepsis.
Inhibition of the RAGE pathway may be an effective approach
for treatment of sepsis in clinical settings. Further pre-clinical
and clinical investigations will be necessary to determine the
feasibility of this strategy in humans with life-threatening sep-
sis or septic shock.
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